BR112013033944A2 - combinação sinérgica - Google Patents
combinação sinérgicaInfo
- Publication number
- BR112013033944A2 BR112013033944A2 BR112013033944A BR112013033944A BR112013033944A2 BR 112013033944 A2 BR112013033944 A2 BR 112013033944A2 BR 112013033944 A BR112013033944 A BR 112013033944A BR 112013033944 A BR112013033944 A BR 112013033944A BR 112013033944 A2 BR112013033944 A2 BR 112013033944A2
- Authority
- BR
- Brazil
- Prior art keywords
- synergistic combination
- synergistic
- combination
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161504744P | 2011-07-06 | 2011-07-06 | |
EP11172865 | 2011-07-06 | ||
PCT/EP2012/063207 WO2013004806A1 (en) | 2011-07-06 | 2012-07-06 | Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013033944A2 true BR112013033944A2 (pt) | 2017-12-19 |
Family
ID=47436548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013033944A BR112013033944A2 (pt) | 2011-07-06 | 2012-07-06 | combinação sinérgica |
Country Status (10)
Country | Link |
---|---|
US (1) | US20140234298A1 (pt) |
EP (1) | EP2729498A1 (pt) |
JP (1) | JP2014520784A (pt) |
KR (1) | KR20140061379A (pt) |
CN (1) | CN103827143A (pt) |
AU (2) | AU2012280267B2 (pt) |
BR (1) | BR112013033944A2 (pt) |
CA (1) | CA2839513A1 (pt) |
RU (1) | RU2013156435A (pt) |
WO (1) | WO2013004806A1 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY175388A (en) | 2012-09-20 | 2020-06-23 | Morphosys Ag | Treatment for rheumatoid arthritis |
WO2016079276A1 (en) * | 2014-11-21 | 2016-05-26 | Takeda Gmbh | Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease |
EP3108897A1 (en) * | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
CR20170537A (es) * | 2015-06-24 | 2018-02-20 | Hoffmann La Roche | Anticuerpos contra csf-1r humano para uso en la inducción de linfocitosis en linfomas o leucemias. |
GB201519331D0 (en) * | 2015-11-02 | 2015-12-16 | Glaxosmithkline Ip Dev Ltd | Treatment paradigm |
US20190218284A1 (en) * | 2016-09-01 | 2019-07-18 | The Regents Of The University Of Colorado A Body Corporate | Methods of treating eosinophilic gastrointestinal diseases |
AU2017370942A1 (en) | 2016-12-07 | 2019-06-13 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
CA3054632A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
CN111757744A (zh) | 2017-10-02 | 2020-10-09 | 人源股份有限公司 | 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法 |
US10927168B2 (en) | 2017-10-02 | 2021-02-23 | Humanicen, Inc. | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
US10899831B2 (en) | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
US11655293B2 (en) * | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
EP3827016A4 (en) * | 2018-10-15 | 2022-05-04 | Elixiron Immunotherapeutics (Hong Kong) Limited | ANTIBODIES TO GRANULOCYTE AND MACROPHAGE GROWTH FACTOR AND THEIR USES |
CA3116412A1 (en) * | 2018-10-31 | 2020-05-07 | Humanigen, Inc. | Materials and methods for treating cancer |
BR112021008688A2 (pt) * | 2018-11-09 | 2021-08-10 | Kiniksa Pharmaceuticals, Ltd. | tratamento para arterite de célula gigante |
US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
CA3137908A1 (en) * | 2019-04-25 | 2020-10-29 | Actinium Pharmaceuticals, Inc. | Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases |
EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
JP2023546657A (ja) * | 2020-10-26 | 2023-11-07 | キニクサ ファーマシューティカルズ, リミテッド | Gm-csf拮抗薬を用いたがんの治療 |
EP4328243A1 (en) * | 2021-04-20 | 2024-02-28 | Korea University Research and Business Foundation | Asymmetric antibody with improved cytotoxicity against cancer cell |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
DE69329503T2 (de) * | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
MXPA01004648A (es) | 1998-11-09 | 2002-05-06 | Idec Pharma Corp | Tratamientro de enfermedades hematologicas malignas asociadas con celulas tumorales de la circulacion usando el anticuerpo quimerico anti-cd20. |
CN1192796C (zh) | 1999-02-12 | 2005-03-16 | 斯克里普斯研究学院 | 联合应用抗血管生成和免疫治疗以治疗肿瘤和转移的方法 |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
JP2006500905A (ja) | 2002-02-13 | 2006-01-12 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ヒト化gm−csf抗体 |
WO2003068821A2 (en) | 2002-02-14 | 2003-08-21 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
EP3284753B1 (en) | 2002-10-17 | 2019-06-05 | Genmab A/S | Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis |
ES2545769T3 (es) | 2005-04-18 | 2015-09-15 | Amgen Research (Munich) Gmbh | Anticuerpos neutralizantes del factor estimulante de colonias de granulocitos y macrófagos humano |
NZ564027A (en) * | 2005-05-18 | 2011-06-30 | Morphosys Ag | Anti-GM-CSF antibodies and uses therefor |
MX2007014497A (es) * | 2005-05-20 | 2008-02-07 | Genentech Inc | Pretratamiento de una muestra biologica de un sujeto con enfermedad autoinmune. |
JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
US20070136826A1 (en) | 2005-12-02 | 2007-06-14 | Biogen Idec Inc. | Anti-mouse CD20 antibodies and uses thereof |
ES2609088T3 (es) * | 2006-02-08 | 2017-04-18 | Morphotek, Inc. | Péptidos GM-CSF antigénicos y anticuerpos anti-GM-CSF |
CA2670288C (en) * | 2006-11-21 | 2015-10-27 | Kalobios Pharmaceuticals, Inc. | Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
CA2687791A1 (en) | 2007-05-23 | 2008-11-27 | Crc For Asthma And Airways Ltd | Neutralizing antibodies |
JP2010532749A (ja) * | 2007-06-07 | 2010-10-14 | サーモディクス ファーマシューティカルズ, インコーポレイテッド | 質量を削減した長時間作用剤形 |
TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
US20100297135A1 (en) | 2007-11-12 | 2010-11-25 | Crc For Asthma And Airways Ltd. | Epitope for neutralizing antibodies |
ES2401536T3 (es) | 2007-11-13 | 2013-04-22 | Evec Inc. | Anticuerpos monoclonales que se unen a HGM-CSF y composiciones medicinales que los comprenden |
MX2010011761A (es) | 2008-04-28 | 2010-11-30 | Kalobios Pharmaceuticals Inc | Anticuerpos para el factor que estimula la colonia del granulocito-macrofago. |
US9353180B2 (en) | 2008-04-29 | 2016-05-31 | Amgen Research (Munich) Gmbh | Method of treatment by the administration of inhibitors of GM-CSF and IL-17 |
US20100122819A1 (en) | 2008-11-17 | 2010-05-20 | Baker Hughes Incorporated | Inserts with Swellable Elastomer Seals for Side Pocket Mandrels |
MX2011008611A (es) * | 2009-02-16 | 2011-10-21 | Biolex Therapeutics Inc | Anticuerpos anti-cd20 humanizados y metodos de uso. |
AR075982A1 (es) | 2009-03-31 | 2011-05-11 | Roche Glycart Ag | Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion |
SG175305A1 (en) * | 2009-04-23 | 2011-11-28 | Theraclone Sciences Inc | Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies |
-
2012
- 2012-07-06 EP EP12735498.3A patent/EP2729498A1/en not_active Withdrawn
- 2012-07-06 CN CN201280033421.3A patent/CN103827143A/zh active Pending
- 2012-07-06 AU AU2012280267A patent/AU2012280267B2/en not_active Ceased
- 2012-07-06 WO PCT/EP2012/063207 patent/WO2013004806A1/en active Application Filing
- 2012-07-06 KR KR1020147003186A patent/KR20140061379A/ko not_active Application Discontinuation
- 2012-07-06 BR BR112013033944A patent/BR112013033944A2/pt not_active IP Right Cessation
- 2012-07-06 JP JP2014517813A patent/JP2014520784A/ja active Pending
- 2012-07-06 RU RU2013156435/10A patent/RU2013156435A/ru not_active Application Discontinuation
- 2012-07-06 US US14/130,667 patent/US20140234298A1/en not_active Abandoned
- 2012-07-06 CA CA2839513A patent/CA2839513A1/en not_active Abandoned
-
2016
- 2016-03-18 AU AU2016201736A patent/AU2016201736A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN103827143A (zh) | 2014-05-28 |
AU2012280267A1 (en) | 2014-01-16 |
KR20140061379A (ko) | 2014-05-21 |
WO2013004806A1 (en) | 2013-01-10 |
AU2016201736A1 (en) | 2016-04-07 |
AU2012280267B2 (en) | 2016-04-21 |
JP2014520784A (ja) | 2014-08-25 |
EP2729498A1 (en) | 2014-05-14 |
CA2839513A1 (en) | 2013-01-10 |
RU2013156435A (ru) | 2015-08-20 |
US20140234298A1 (en) | 2014-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2021029I1 (no) | tukatinib | |
BR112013033944A2 (pt) | combinação sinérgica | |
DK2744810T4 (da) | Tenofovir-alafenamid-hemifumarat | |
DK2769050T3 (da) | Propsensor | |
BR112014000879A2 (pt) | deflegmador | |
DK3272861T3 (da) | Alpha-galactosidase-sammensætninger | |
CO6960543A2 (es) | 2-tiopirimidinonas | |
DE102011100082A8 (de) | Traygreifvorrichtung | |
CO6970601A2 (es) | Nueva combinación | |
FI20116167L (fi) | Järjestely | |
DK3141251T3 (da) | Koloskopi - forberedelse | |
DE112011104936A5 (de) | Stanzstauchniet | |
DE112012000958A5 (de) | Handsäge | |
DK2476953T3 (da) | Fluidbedkedel | |
BR112013032539A2 (pt) | composição microbicida sinérgica | |
DE112012002458A5 (de) | Hydrotransformator | |
DE112012000819A5 (de) | Gurtbandfänger | |
DE112012005313A5 (de) | Leuchtbild | |
DK2526750T3 (da) | Høbjærgningsmaskine | |
DE112012001294T8 (de) | Umspritzungsverfahren | |
DE102011117169A8 (de) | Absetzplattenanordnung | |
DE112011105396A5 (de) | Nachverfestigungsverfahren | |
FI20115579A0 (fi) | Järjestely | |
DK2681057T3 (da) | Nanofiber-mærkning | |
ES1076319Y (es) | Minisalvavidas acuatico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15I | Others concerning applications: loss of priority |
Free format text: PERDA DA PRIORIDADE US 61/504,744, REIVINDICADA NO PCT/EP2012/063207, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT ("MORPHOSYS AG") SER DISTINTO DAQUELE QUE DEPOSITOU A PRIORIDADE REIVINDICADA E, MESMO APOS A ELABORACAO DE EXIGENCIA PARA TAL, NAO FOI REGULARIZADO O DOCUMENTO COMPROBATORIO DE CESSAO DA CITADA PRIORIDADE ACOMPANHADO DE SUA RESPECTIVA TRADUCAO, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, ITEM 27 DO ATO NORMATIVO 128/97 E NO ART. 2 DA RESO |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |